453 Results

People

  1. Hudis
    Hudis
  2. Norton
    Norton
  3. Robson
    Robson
  4. Offit
    Offit
  5. Seidman
    Seidman
  6. Gilewski
    Gilewski
  7. Patil
    Patil
  8. Fornier
    Fornier
  9. Panageas
    Panageas
  10. Solit
    Solit

Groups

  1. Breast Medicine Service (453)
  2. Department of Medicine (453)
  3. Solid Tumor Oncology Division (453)
  4. Survivorship Research (333)
  5. Population Sciences Research Program (192)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (149)
  7. Epidemiology and Biostatistics (143)
  8. GSK Faculty (143)
  9. Surgery (107)
  10. Biostatistics Service (106)
  1. "adult"
  2. "Solid Tumor Oncology Division"
  3. "Breast Medicine Service"
Formats
  1. Journal Article (435)
  2. Conference Paper (6)
  3. Review (5)
  4. Research Letter (3)
  5. Editorial (2)
  6. Guidelines (1)
  7. Meeting Abstract (1)
Groups
  1. Breast Medicine Service (453)
  2. Department of Medicine (453)
  3. Solid Tumor Oncology Division (453)
  4. Survivorship Research (333)
  5. Population Sciences Research Program (192)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (149)

More Groups

People
  1. Clifford Hudis (129)
  2. Larry Norton (129)
  3. Mark Robson (117)
  4. Kenneth Offit (77)
  5. Andrew Seidman (63)
  6. Teresa Gilewski (37)

More People

Years
  1. 2024 (8)
  2. 2023 (25)
  3. 2022 (23)
  4. 2021 (19)
  5. 2020 (14)
  6. 2019 (18)

More Years

Publications
  1. Journal of Clinical Oncology (51)
  2. Cancer (41)
  3. Breast Cancer Research and Treatment (33)
  4. Clinical Cancer Research (31)
  5. Clinical Breast Cancer (16)
  6. Annals of Surgical Oncology (15)

More Publications

Publishers
  1. American Society of Clinical Oncology (60)
  2. Springer (60)
  3. Wiley Blackwell (50)
  4. Elsevier Inc. (49)
  5. American Association for Cancer Research (45)
  6. Oxford University Press (31)

More Publishers

Results (453)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Management of patients with advanced-stage HER2-positive breast cancer: Current evidence and future perspectives
    Review

    Marra, A.; Chandarlapaty, S.; Modi, S.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • BRAF — A tumour-agnostic drug target with lineage-specific dependencies
    Review

    Hanrahan, A. J.; Chen, Z.; Rosen, N.; Solit, D. B.
    Nature Reviews Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)
    Journal Article

    Saura, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. B.; Tamura, K.; Iwata, H.; Tsurutani, J.; Sohn, J.; Mathias, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-in-human evaluation of site-specifically labeled (89)Zr-pertuzumab in patients with HER2-positive breast cancer
    Journal Article

    Yeh, R.; O'Donoghue, J. A.; Jayaprakasam, V. S.; Mauguen, A.; Min, R.; Park, S.; Brockway, J. P.; Bromberg, J. F.; Zhi, W. I.; Robson, M. E.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Journal Article

    Grieve, C.; Joseph, A.; Drullinsky, P.; Zelenetz, A. D.; Hamlin, P.; Kumar, A.
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Impact of reactive changes on multigene testing: Histopathologic analysis of low-grade breast cancers with high-risk 21-gene recurrence scores
    Journal Article

    Grabenstetter, A.; Brogi, E.; Thompson, D. M.; Blinder, V. S.; Norton, L.; Morrow, M.; Robson, M. E.; Wen, H. Y.
    Breast Cancer Research and Treatment (2024)

    Fulltext@MSK | Save
  • Cost-effectiveness of adjuvant olaparib for patients with breast cancer and germline BRCA1/2 mutations journal article
    Journal Article

    Zettler, C. M.; De Silva, D. L.; Blinder, V. S.; Robson, M. E.; Elkin, E. B.
    JAMA Network Open (2024)

    Fulltext@MSK | Save
  • Symptomatic necrosis with antibody-drug conjugates and concurrent stereotactic radiotherapy for brain metastases
    Research Letter

    Lebow, E. S.; Pike, L. R. G.; Seidman, A. D.; Moss, N.; Beal, K.; Yu, Y.
    JAMA Oncology (2023)

    Fulltext@MSK | Save
  • Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic/machine learning model
    Journal Article

    Hughes, J. H.; Tong, D. M. H.; Burns, V.; Daly, B.; Razavi, P.; Boelens, J. J.; Goswami, S.; Keizer, R. J.
    CPT: Pharmacometrics and Systems Pharmacology (2023)

    Fulltext@MSK | Save